The epidemic of obesity and its associated comorbidities represents a medicinal challenge that recruits broad molecular diversity. We have pioneered the application of endogenous hormones and physiological mechanisms optimized for pharmacological purposes as a means to address the broad heterogeneity constituted by the multiple diseases associated with the metabolic syndrome. From the earliest demonstration with lispro-insulin to the most recent discovery of incretin-based poly-pharmacophores we have pursued the discovery of therapeutics directed at the successful management of insulin-dependent diabetes, obesity and related diseases. We have coined the term “chemical biotechnology” to reflect the integration of classical small and large molecule-based chemistries. The integrated pharmacology of these peptides, proteins and nuclear hormones has provided a library of medicinal agents to be interrogated in cardio-metabolic diseases References “Targeted Estrogen Delivery Reverses The Metabolic Syndrome” Nature Medicine Nature MedicineVolume:18:1847 “Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans” Sci. Trans. Med. (2013), 5:209 “Chemical Synthesis of Insulin Analogs Through a Novel Precursor” ACS Chem. Biol., (2014), 9:683 “Break on Through to the Other 1” Cell Metabolism (2014), 20:554 “A Rationally Designed Peptide of Triple Gut Hormone Action Cures Obesity and Diabetes” Nature Medicine (2014), doi:10.1038/nm.3761

Award Address (Alfred Burger Award in Medicinal Chemistry sponsored by Gilead Sciences, Inc.). Chemical biotechnology applied to metabolic diseases

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.